Latest Updates

Oct 19, 2026 TRIANA Biomedicines Announces Participation in Goldman Sachs’ Healthcare Private Company Conference Read More Sep 9, 2026 TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611 Read More Sep 2, 2026 TRIANA Biomedicines Announces Participation in Upcoming Investor Conferences Read More May 18, 2026 TRIANA Biomedicines Announces the Appointment of Mohan Bala as Chief Operating Officer and Attracts Leading Experts to its Scientific Advisory Board Read More Apr 15, 2026 TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026 Read More Mar 25, 2026 TRIANA Biomedicines’ TRI-611 Granted U.S. FDA Fast Track Designation for Treatment of ALK Positive Non-small Cell Lung Cancer Read More Mar 19, 2026 TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK Positive Non-small Cell Lung Cancer Read More Jan 6, 2026 TRIANA Biomedicines Enters into a Research Collaboration with Johnson & Johnson to Identify Oncology Molecular Glue Degraders Read More Dec 12, 2025 Pfizer and TRIANA Biomedicines Named Recipients of Scrip’s 2025 Best Partnership Alliance Award for Their Collaboration on Molecular Glue Degraders Read More Dec 3, 2025 TRIANA Biomedicines Announces the Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline Read More